Skip to main content

Table 1 The basic and clinical features of non-metastatic PDAC

From: Effect of neoadjuvant radiotherapy on survival of non-metastatic pancreatic ductal adenocarcinoma: a SEER database analysis

Characteristics

Level

Number (%)

Insurance Recode

Insured

17,218(81.87%)

 

No/unknown

3812(18.13%)

Marital status

Married

13,291(63.20%)

 

Single

6984(33.21%)

 

Unknown

755(3.59%)

Age, years

< 65

9427(44.83%)

 

≥65

11,603(55.17%)

Race recode

White

17,170(81.65%)

 

Other

3860(18.35%)

Sex

Male

10,657(50.68%)

 

Female

10,373(49.32%)

Tumor site

Pancreas Head

13,576(64.56%)

 

Pancreas Body Tail

5175(24.61%)

 

Pancreas Other

2279(10.83%)

Grade

I

4147(19.72%)

 

II

8677(41.26%)

 

III/IV

6075(28.89%)

 

Unknown

2131(10.13%)

T stage

T1

4242(20.17%)

 

T2

10,699(50.87%)

 

T3

5121(24.36%)

 

T4

968(4.60%)

N stage

N0

9467(45.02%)

 

N1

7400(35.19%)

 

N2

4163(19.79%)

Treatment methods

Only surgery

8903(42.33%)

 

Surgery + chemotherapy

6386(30.37%)

 

Neoadjuvant radiotherapy

776(3.69%)

 

Adjuvant radiotherapy

4965(23.61%)

Regional nodes examined

< 15

11,410(54.26%)

≥15

9437(44.87%)

Unknown

183(0.87%)

  1. PDAC Pancreatic Ductal Adenocarcinoma